04:44 AM EDT, 06/13/2025 (MT Newswires) -- Moderna ( MRNA ) said late Thursday that the US Food and Drug Administration has approved its mRESVIA vaccine to prevent lower respiratory tract disease caused by respiratory syncytial virus in individuals aged 18 to 59 years who are at increased risk for disease.

The vaccine was previously approved for adults aged 60 years and above.

The company said it plans have mRESVIA available for both younger adults at increased risk and older adults in the US for the 2025-2026 respiratory virus season.

Moderna ( MRNA ) shares were down 1.8% in recent premarket activity Friday.